March 14th 2024
In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
Addressing Unmet Needs and Treatment Gaps in the Clinical Management of Neovascular Age-Related Macular Degeneration: Practical Strategies for Pharmacists in Specialty and Man...
1.5 Credits / Ophthalmology/Optometry
View More
Management of Neuromyelitis Optica Spectrum Disorder: Expert Insights and Updates for Pharmacists, featuring a Patient Perspective
1.5 Credits / Ophthalmology/Optometry
View More
The Promising Role of Novel Targeted Therapies in Addressing Clinical and Economic Burdens in Diabetic Macular Edema
1.5 Credits / Ophthalmology/Optometry
View More
Improving Outcomes and Quality of Care in Age-Related Macular Degeneration and Diabetic Macular Edema: Patient-Centered Strategies in Managed Care
3.0 Credits / Ophthalmology/Optometry
View More
Maximizing Patient Outcomes in Ophthalmologic Diseases: How Managed Care Professionals Play a Key Role in Facilitating Uptake of Biosimilars
1.0 Credit / Ophthalmology/Optometry
View More
Providers Exploit Minor Differences Between Innovator Drugs and Biosimilars
November 24th 2020Minute differences between biosimilars and reference products are not considered “clinically meaningful,” but these differences are exploitable when it comes to addressing allergies related to originator products.